問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳其敬

Recruiting

List

144Cases

2019-04-01 - 2027-11-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-02-01 - 2026-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-08-01 - 2024-11-29

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-10-01 - 2021-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2026-01-15 - 2043-05-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-08-01 - 2027-04-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2020-10-01 - 2025-12-31

Phase I

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

  • Condition/Disease

    Relapsed/Refractory Acute Myeloid Leukemia

  • Test Drug

    RO7283420

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

1 11 12 13 14 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB